grant
Stroke volUme-baSed fluid resusciTAtIoN in AP (SUSTAIN)
Organization UNIVERSITY OF SOUTHERN CALIFORNIALocation Los Angeles, UNITED STATESPosted 12 Sept 2025Deadline 11 Sept 2028
NIHUS FederalResearch GrantFY20252-arm trial3-10CAMCF-IAbscissionAcademic Medical CentersAdverse ExperienceAdverse eventAlgorithmsAmericanB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BiochemicalBlood SerumBody WeightBrittle Diabetes MellitusCCL2CCL2 geneCXCL8Cessation of lifeChemokine, CC Motif, Ligand 2ClinicalClinical TrialsCritical IllnessCritically IllDataDeathDevicesDiseaseDisorderDysfunctionEducational workshopEnrollmentExcisionExtirpationFDA approvedFIZZ3FingersFluid TherapyFluid overloadFound in Inflammatory Zone 3FoundationsFunctional disorderFundingGCP1Gastrointestinal DiseasesGoalsHPGFHartmann's solutionHepatocyte-Stimulating FactorHospital AdmissionHospitalizationHourHybridoma Growth FactorHydrationHydration statusIDDMIFN-beta 2IFNB2IL-6IL-8IL6 ProteinIL8IL8 geneIV FluidIncidenceIndividualInflammation MediatorsInsulin-Dependent Diabetes MellitusInterleukin-6Intravenous FluidInvestigatorsJuvenile-Onset Diabetes MellitusK60Ketosis-Prone Diabetes MellitusKnowledgeLactated Ringer's SolutionLegLength of StayLiquid substanceMCAFMCP-1MCP1MGI-2MaintenanceMeasurementMethodsModelingMolecular FingerprintingMolecular ProfilingMonocyte Chemoattractant Protein-1Monocyte Chemotactic Protein-1Monocyte Chemotactic and Activating FactorMonocyte Chemotactic and Activating ProteinMonocyte Chemotactive and Activating FactorMonocyte Secretory Protein JEMorbidityMorbidity - disease rateMyeloid Differentiation-Inducing ProteinNIDDKNational Institute of Diabetes and Digestive and Kidney DiseasesNational Institutes of HealthNumber of Days in HospitalOrganOrgan failureOutcomePancreatitisPathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPhasePhysiologicPhysiologicalPhysiopathologyPilot ProjectsPlasmacytoma Growth FactorPopulation HeterogeneityProcessRETNRandomization trialRandomizedRandomized, Controlled TrialsRecordsRemovalReproducibilityResearchResearch PersonnelResearchersResuscitationRinger's lactateRiskSCYA2SCYB8SepsisSerumSmall Inducible Cytokine A2Stroke VolumeSudden-Onset Diabetes MellitusSurgical RemovalSymptomsSystemic Inflammatory Response SyndromeT1 DMT1 diabetesT1DT1DMTSG-1TestingTherapeutic InterventionTherapeutic TrialsTimeType 1 Diabetes MellitusType 1 diabetesType I Diabetes MellitusUnited StatesUnited States National Institutes of HealthUniversity Medical CentersValidationWeightWorkshopacute pancreatitisarmb-ENAPbody fluid balance therapycatalystclinical centercomparable efficacycomparative efficacycompare efficacycostdesigndesigningdiagnostic criteriadiverse populationsenrollethnic diversityethnically diverseexperiencefeasibility trialfluidgastrointestinalgastrointestinal disorderheterogeneous populationhospital dayshospital length of stayhospital stayhypervolemiaimprovedindividual patientinflammatory mediatorinsulin dependent diabetesinsulin dependent type 1interferon beta 2intervention therapyjuvenile diabetesjuvenile diabetes mellitusketosis prone diabetesliquidmembermolecular profilemolecular signaturemortalitynew approachesnovelnovel approachesnovel strategiesnovel strategypathophysiologypathwaypatient oriented outcomespatient populationpilot studypilot trialpopulation diversitypreventpreventingprimary end pointprimary endpointrandomisationrandomizationrandomized control trialrandomized trialrandomly assignedresectionresistinrestorationrisk mitigationtwo-arm trialtype I diabetestype one diabetesvalidationsweights
Description preview
PROJECT SUMMARY/ABSTRACT:
Acute Pancreatitis (AP) is a leading gastrointestinal cause of gastrointestinal hospitalization in the United States
with substantial mortality (>5000 deaths), rising incidence (>3% annually), and high cost of 5 billion $US annually.
Nevertheless, there are no FDA approved treatments for AP. Recent National Institute of…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click